AS01B Adjuvant Mechanisms and CD4 T Cell Responses

Overview

AS01B adjuvant induces robust and durable CD4 T cell responses via a two-phase mechanism of transient inflammatory cytokine induction followed by sustained IFN-signaling pathway activation that drives context-dependent Th1 or Th2 polarization.

Abstract

AS01B adjuvant induces CD4 T cell responses through a two-phase mechanism involving initial transient inflammatory activation followed by sustained IFN-signaling pathway engagement. Studies demonstrate that AS01B triggers early innate responses including IL-6 and CRP peaking at 24 hours post-vaccination, followed by IFN-γ upregulation and activation of IFN-inducible genes (STAT1, IRF1, MX1, CXCL10) after the second dose. This innate activation directly correlates with enhanced CD4+ T cell outcomes, as multi-parametric modeling shows associations between CRP, IL-6, IFN-signaling pathway activation and subsequent CD4 responses. AS01B consistently induces superior CD4 T cell responses compared to other adjuvants, with exceptional durability extending 18-36+ months post-vaccination.

Mechanisms of AS01B at the Innate Immunity Level

• Cytokines Induced: IL-6, IFN-γ, CRP, IP-10
• Signaling Pathways: IFN-signaling, PPAR, FcεRI, TGF-β pathways
• Timeline of Responses: Peak IL-6 at 24 hours, IFN-γ and IP-10 increases at days 31 and 33
• Gene Expression Changes: Upregulation of IFN-inducible genes (STAT1, IRF1, MX1, CXCL10)

CD4 T Cell Responses Induced by AS01B

• Proliferation/Activation Markers: Median 963 CSP-specific CD4+ T cells per 10^6 CD4+ T cells
• Cytokine Production: Higher ex vivo IFN-γ ELISPOTs
• Functional Assays: AIM assay showed more robust PfRH5-specific CD4+ T cell response
• Persistence/Durability: Responses remained detectable at 18 months post-immunization; persisting for at least 3 years after primary vaccination

Mechanism-Response Links

• Evidence showing associations between innate responses and CD4 outcomes, particularly activation of IFN-signaling pathway
• Expression of genes related to Tfh and Th2 cell differentiation in AS01B vaccinees

Comparative Adjuvant Effects

• AS01B demonstrated superior CD4 T cell induction compared to all tested adjuvants
• Potency Ranking: AS01B ≥ AS01E > AS03 > AS04 > Alum
• Mechanistically shared IFN-signaling pathway activation with AS03 but induced higher magnitude innate responses

Key Findings

• Mechanism of Action: AS01B induces a higher-magnitude antigen-specific cTfh cell response with a greater Th2/Tfh2 skew
• Clinical Relevance: AS01B enhances protection against pathogens requiring antibody-mediated immunity
• Limitations: Small sample sizes affect some statistical power of correlations

References

1. M. Fochesato et al., "Comparative preclinical evaluation of AS01 versus other Adjuvant Systems..."
2. G. Leroux-Roels et al., "Impact of adjuvants on CD4(+) T cell and B cell responses..."
3. I. Leroux-Roels et al., "Strong and persistent CD4+ T-cell response in healthy adults..."
4. P. Vandepapelière et al., "Vaccine adjuvant systems containing monophosphoryl lipid A..."
5. C. Nielsen et al., "Protein/AS01B vaccination elicits stronger..."
6. W. Burny et al., "Different Adjuvants Induce Common Innate Pathways..."
7. S. Pichyangkul et al., "Pre-clinical evaluation of the malaria vaccine candidate..."
8. K. Kester et al., "Randomized, double-blind, phase 2a trial of falciparum malaria vaccines..."
9. G. Leroux-Roels et al., "Immunogenicity and Safety of a Booster Dose..."
10. C. Brando et al., "Murine Immune Responses to Liver-Stage Antigen 1 Protein..."